Skip to main content

Observe Medical ASA (OSL:OBSRV)

Norway flag Norway · Delayed Price · Currency is NOK
1.160
-0.010 (-0.85%)
At close: Apr 28, 2026
44.10%
Market Cap 157.93M
Revenue (ttm) 18.81M
Net Income (ttm) -48.64M
Shares Out 136.15M
EPS (ttm) -0.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 307,811
Average Volume 718,305
Open 1.170
Previous Close 1.170
Day's Range 1.130 - 1.190
52-Week Range 0.525 - 3.140
Beta -0.02
RSI 57.94
Earnings Date Apr 30, 2026

About Observe Medical ASA

Observe Medical ASA develops and commercialize medical technology products for patients, healthcare professionals, and hospitals in Norway, Sweden, the United States, and rest of European countries. It offers Sippi, a digital and automated urine measurement system for urine monitoring and biofilm control; and Biim, a wireless pocketable ultrasound device for display of the ultrasound image and video for nurses and medical staff. The company also offers Unometer, Safeti Plus, Unometer 500, UnoMeter, and AbdoPressure products used for drainage, c... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2009
Employees 4
Stock Exchange Oslo Børs
Ticker Symbol OBSRV
Full Company Profile

Financial Performance

In 2025, Observe Medical ASA's revenue was 18.81 million, an increase of 1.77% compared to the previous year's 18.48 million. Losses were -48.64 million, -17.18% less than in 2024.

Financial Statements

News

Observe Medical ASA Transcript: Trading update

Sales grew 80% year-on-year, driven by new product launches and expanded distribution, with the business now present in 46 countries and targeting a NOK 2.6 billion market. The company expects to reach cash positivity this year and continues to innovate with products like UnoMeter Safeti Max.

4 weeks ago - Transcripts

Observe Medical ASA Transcript: Trading Update

Oona Meter products saw 61% growth and expanded to 44 countries, with order intake surpassing NOK 25 million. New infection control innovations and product launches are on track, while significant debt reduction and a new investor have strengthened financials.

7 months ago - Transcripts

Observe Medical ASA Transcript: Trading update

A robust proprietary and partnered product strategy has positioned the business as a leader in urine output measurement, with a strong global distribution network and accelerating order intake. Key product launches and debt restructuring agreements support ambitions for profitability and growth.

1 year ago - Transcripts

Observe Medical ASA Earnings Call Transcript: Q2 2024

H1 2024 saw NOK 13.1 million in revenue and a gross margin of 38.2%, with the launch of UnoMeter Safeti Plus expected to drive future growth. A NOK 22 million private placement strengthened liquidity, and new partnerships and product launches are set to expand market reach.

1 year ago - Transcripts

Observe Medical ASA Earnings Call Transcript: Q4 2023

2 years ago - Transcripts

Observe Medical ASA Earnings Call Transcript: Q4 2022

3 years ago - Transcripts

Observe Medical ASA Earnings Call Transcript: Q3 2022

3 years ago - Transcripts